In our latest interview, we spoke to Jean-Pierre Paccaud, Director of Business Development & Corporate Strategy at GARDP, about the drug developer’s model and his thoughts on the wider field.
For the first time, Brazilian researchers have demonstrated the efficacy of the Zika virus in treating advanced-stage human CNS tumors in vivo.
The results of the MERINO trial have been reported at ECCMID, revealing the combination treatment piperacillin-tazobactam is significantly less effective than meropenem in treating some bloodstream infections.
Two genetically-modified broadly-neutralizing antibodies have been demonstrated to elicit long-term protection against an HIV-like virus in rhesus macaques, with a Phase I clinical trial now underway.
In this interview, we speak to Dr. Bryan Kraft, an Assistant Professor of Medicine at Duke University, about his research into carbon monoxide as a potential therapy to treat ARDS and the clinical trial for this therapy that is currently underway.
Partnership announcements and promising trial data reported at the 2018 Conference on Retroviruses and Opportunistic Infections, take a look at our round-up of the latest industry headlines.
A small clinical trial has demonstrated that an IL-7 drug that revs up the body’s immune system holds promise in sepsis patients, potentially offering a new approach to improve survival rates.
Listen to the top stories in infectious diseases this week, including novel CRISPR-based diagnostics, clinical trial in tuberculosis and the latest CDC approvals for the flu vaccine.
We take a look at the key microbiome therapeutics currently in the clinical pipeline for recurrent C. difficile infections and their prospects for the treatment of this disease in the future.
A Phase II trial has suggested potential for new Bacille Calmette–Guerin revaccination strategies in addition to hope for subunit vaccines against tuberculosis.
